Established, emerging and future roles of PET/CT in the management of colorectal cancer

R A Herbertson; A F Scarsbrook; S T Lee; N Tebbutt; A M Scott

doi:10.1016/j.crad.2008.08.008

Established, emerging and future roles of PET/CT in the management of colorectal cancer

Clin Radiol. 2009 Mar;64(3):225-37. doi: 10.1016/j.crad.2008.08.008. Epub 2008 Oct 23.

Authors

R A Herbertson¹, A F Scarsbrook, S T Lee, N Tebbutt, A M Scott

Affiliation

¹ Ludwig Institute for Cancer Research, Melbourne Centre for Clinical Sciences, Austin Health, Heidelberg, Victoria, Australia. rebecca.herbertson@ludwig.edu.au

PMID: 19185652
DOI: 10.1016/j.crad.2008.08.008

Abstract

Positron-emission tomography-computed tomography (PET/CT) is rapidly being integrated into the imaging pathways of several different tumour types, most frequently using the glucose analogue 2- [(18)F]-fluoro-2-deoxy-D-glucose (FDG). Integrated FDG-PET/CT combines functional and anatomical imaging to improve sensitivity and specificity of tumour detection. The aim of this article is to review the established, emerging, and future roles of FDG-PET/CT in the management of patients with colorectal cancer (CRC).

Publication types

Review

MeSH terms

Colonoscopy
Colorectal Neoplasms / diagnostic imaging*
Colorectal Neoplasms / drug therapy
Cost-Benefit Analysis
Fluorodeoxyglucose F18
Humans
Neoplasm Recurrence, Local / diagnostic imaging
Neoplasm Staging
Neoplasm, Residual
Positron-Emission Tomography / economics
Positron-Emission Tomography / methods*
Positron-Emission Tomography / trends
Radiopharmaceuticals
Radiotherapy Planning, Computer-Assisted
Sensitivity and Specificity
Tomography, X-Ray Computed / economics
Tomography, X-Ray Computed / methods*
Tomography, X-Ray Computed / trends
United Kingdom

Substances

Radiopharmaceuticals
Fluorodeoxyglucose F18